Risperidone dosing pattern and clinical outcome in psychosis: An analysis of 1713 cases

被引:4
作者
Kim, CY
Shin, YW
Joo, YH
Hong, JP
Lee, GH
Choi, SK
机构
[1] Univ Ulsan, Coll Med, Dept Psychiat, Asan Med Ctr, Seoul, South Korea
[2] Sogang Univ, Coll Business Adm, Seoul, South Korea
[3] Janssen Korea Med Dept, Seoul, South Korea
关键词
D O I
10.4088/JCP.v66n0711
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background: In treating patients with psychosis, practicing clinicians use various dosing strategies of antipsychotic medications, including risperidone. To evaluate the outcome of different risperidone dosing strategies in clinical practice, we undertook a large, prospective, naturalistic study in which daily dosage was determined freely by local standards of care. Method: In a 6-week trial between December 2000 and January 2002, 1713 patients with DSM-IV schizophrenia and related psychoses were treated with risperidone, with the dose, daily changes in dose, and weekly changes in Brief Psychiatric Rating Scale score documented. Cluster analysis was performed to identify homogeneous dosing patterns among the heterogeneous total population. Results: Of the 6 dosing patterns identified by cluster analysis, a 2-week titration cluster, with a starting dose of 1.8 mg/day titrated to a maximum dose of 4.7 mg/day at day 14, and a I -week titration cluster, with a starting dose of 2.6 mg/day titrated to a maximum dose of 5.4 mg/day at day 7, showed superior clinical outcomes compared with the other clusters, in which titrations were slower and higher. Conclusion: Our results indicate that the current consensus regarding risperidone dosing is appropriate for clinical practice, whereas a slower titration schedule does not guarantee a better clinical outcome, thus emphasizing the need for appropriate early titration.
引用
收藏
页码:887 / 893
页数:7
相关论文
共 20 条
[1]   Maintenance treatment in bipolar disorder [J].
Baldessarini, RJ ;
Tohen, M ;
Tondo, L .
ARCHIVES OF GENERAL PSYCHIATRY, 2000, 57 (05) :490-492
[2]  
CHOUINARD G, 1993, J CLIN PSYCHOPHARM, V13, P25
[3]   Risperidone versus haloperidol: I. Meta-analysis of efficacy and safety [J].
Davies, A ;
Adena, MA ;
Keks, NA ;
Catts, SV ;
Lambert, T ;
Schweitzer, I .
CLINICAL THERAPEUTICS, 1998, 20 (01) :58-71
[4]   Cluster analysis of clinical data to identify subtypes within a study population following treatment with a new pentapeptide antidepressant [J].
Feighner, JP ;
Sverdlov, L ;
Nicolau, G ;
Noble, JF .
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2000, 3 (03) :237-242
[6]  
Guy W., 1976, ECDEU ASSESSMENT MAN, P217, DOI DOI 10.1016/J.BIOPHA.2016.11.034
[7]   Comparison of discharge rates and drug costs for patients with schizophrenia treated with risperidone or olanzapine [J].
Kelly, DL ;
Nelson, MW ;
Love, RC ;
Yu, Y ;
Conley, RR .
PSYCHIATRIC SERVICES, 2001, 52 (05) :676-678
[8]   The classification of first episode schizophrenia:: a cluster-analytical approach [J].
Lastra, I ;
Vázquez-Barquero, JL ;
Castanedo, SH ;
Cuesta, MJ ;
Vázquez-Bourgon, ME ;
Dunn, G .
ACTA PSYCHIATRICA SCANDINAVICA, 2000, 102 (01) :26-31
[9]   Clinical and biological markers for outcome in schizophrenia - A review of a longitudinal follow-up study in Uppsala Schizophrenia Research Project [J].
Lindstrom, LH .
NEUROPSYCHOPHARMACOLOGY, 1996, 14 (03) :S23-S26
[10]   A dose-outcome analysis of risperidone [J].
Love, RC ;
Conley, RR ;
Kelly, DL ;
Bartko, JJ .
JOURNAL OF CLINICAL PSYCHIATRY, 1999, 60 (11) :771-775